facebook
twitter
rss
account
search
search
 

Drug combo increases brain tumor survival

March 9, 2009 at 2:53 PM   |   Comments

BONN, Germany, March 9 (UPI) -- German and Swiss scientists say they have used the combination of two drugs to achieve a substantial improvement in the treatment of certain brain tumors.

The researchers led by Professor Dr. Ulrich Herrlinger of the University of Bonn treated 39 patients who had been diagnosed with a gliablastoma. The patients -- treated with a combination of temozolomide and lomustine -- survived on average 23.1 months, while with the standard therapy the mean would have been 14.6 months, the researchers said.

"This unusually manifest extension of the survival time has surprised even us," said Herrlinger. "Our results offer the opportunity to improve our grip on this aggressive form of cancer. Now, further investigations involving a larger number of patients are needed to optimize this therapy."

The study is reported in the February issue of the Journal of Clinical Oncology.

© 2009 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended UPI Stories
Featured UPI Collection
trending
Notable deaths of 2014 [PHOTOS]

Notable deaths of 2014 [PHOTOS]

Most Popular
1
You've got mites on your face, and so does everyone else
2
Volcano erupts, Iceland issues then rescinds red alert
3
Latvia boasts world's first net for migrating bats
4
Type Ia supernovas: the zombies of the cosmos
5
New space debris monitoring facility set for Australia
Trending News
Video
x
Feedback